Jenrin Discovery’s IND Application for Its Peripherally Restricted Cannabinoid -1 Receptor Inverse …

CHADDS FORD, PA, USA I December 14, 2017 I Jenrin Discovery has announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) Application for JD5037, Jenrin’s novel peripherally restricted (PR) CB1 receptor inverse agonist, to begin Phase 1 … Read More

The post Jenrin Discovery’s IND Application for Its Peripherally Restricted Cannabinoid -1 Receptor Inverse … appeared first on Dagga Magazine.

…read more

Leave a Reply

Your email address will not be published. Required fields are marked *